Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Current Leases (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Current Leases data on record, last reported at $2.6 million in Q1 2026.

  • On a quarterly basis, Current Leases rose 159.42% to $2.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.6 million, a 159.42% increase, with the full-year FY2025 number at $2.8 million, up 273.81% from a year prior.
  • Current Leases reached $2.6 million in Q1 2026 per RAPP's latest filing, down from $2.8 million in the prior quarter.
  • Over the last five years, Current Leases for RAPP hit a ceiling of $2.8 million in Q4 2025 and a floor of $670000.0 in Q4 2023.
  • A 4-year average of $1.5 million and a median of $1.0 million in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: grew 10.0% in 2024, then surged 273.81% in 2025.
  • Tracing RAPP's Current Leases over 4 years: stood at $670000.0 in 2023, then increased by 10.0% to $737000.0 in 2024, then soared by 273.81% to $2.8 million in 2025, then fell by 5.08% to $2.6 million in 2026.
  • Business Quant data shows Current Leases for RAPP at $2.6 million in Q1 2026, $2.8 million in Q4 2025, and $2.5 million in Q3 2025.